Over 455 Adverse Events: What the FDA Data on Compounded Peptides Reveals

The scale of the grey market peptide problem became visible in a way that was hard to ignore. The FDA issued more than 50 warning letters to manufacturers of compounded semaglutide and tirzepatide after receiving hundreds of adverse event reports. The lessons extend well beyond GLP-1s.

By UAE Peptide Clinic Research Desk

The scale of the grey market peptide problem became visible in a way that was hard to ignore. The FDA issued more than 50 warning letters to compounders and manufacturers of semaglutide and tirzepatide — the injectable weight-loss peptides — after receiving over 455 adverse event reports linked to compounded versions of these products. The lessons extend well beyond GLP-1s.

What the Adverse Events Showed

Many of the reported adverse events involved dosing errors — patients self-administering from multi-dose vials with no clear dose-per-unit marking. Others involved products labelled with the names of licensed pharmacies that had not compounded them. Some products had counterfeit identifiers: labels designed to create the appearance of regulatory compliance where none existed. Several cases required hospitalisation.

The Broader Pattern

GLP-1 medications are the most prominent current example, but the pattern is not unique to them. Across the peptide market, grey market products frequently misrepresent their origin, their manufacturing standard, and their concentration. The regulatory infrastructure that would catch these discrepancies before a product reaches a patient does not apply to research chemicals. Adverse events go unreported. Patterns go undetected.

A label is not a guarantee. In an unregulated market, it is a marketing decision.

What Pharmacovigilance Requires

In a regulated pharmaceutical system, adverse events are reported, tracked, and acted upon. Product batches are traceable. If a problem is identified, a recall is possible. None of this infrastructure exists for grey market peptides. There is no mechanism for tracking harm, no requirement to report problems, and no ability to trace a contaminated batch back to its source.

At UAE Peptide Clinic, every product we dispense is fully traceable — batch number, pharmacy, dispensing record, prescribing physician. That chain of custody is what patient safety looks like in practice. Book a free consultation at /book.